A compound according to structure USYDS1: ##STR00001##
wherein the compound is in purified form.

A compound according to structure USYDS1: ##STR00001##
wherein the compound is in purified form.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include

##STR00001##

or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include

##STR00001##

or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.

The present invention relates to a process of extraction and purification of a stilbenoid, pterostilbene, from botanical sources. The process involves obtaining pterostilbene having high degree of purity and the present invention also relates to pure form of pterostilbene obtained. The invention also relates to complexing the pterostilbene with carriers such as cyclodextrin for improving its water solubility and bioavailability. The present invention also describes a process for inhibition of Histone Deacetylases using pterostilbene optionally along with a carrier, and a method of managing Poly Glutamine repeat disorders by the administration of pterostilbene optionally along with a carrier.

Therapeutic compositions comprising one or more agents that inhibit CXXC5-DVL interface, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatment, prevent, and diagnose a condition/disease associated with a metabolic disease or a related clinical condition thereof, are disclosed.

Therapeutic compositions comprising one or more agents that inhibit CXXC5-DVL interface, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatment, prevent, and diagnose a condition/disease associated with a metabolic disease or a related clinical condition thereof, are disclosed.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include ##STR00001##
or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include ##STR00001##
or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.

A compound, composition, or method for treating cancer is disclosed. The compound (that can be used in the composition and/or method) can include

##STR00001##

or pharmaceutically acceptable salts or solvates thereof. R.sup.1a-R.sup.1d, R.sup.2-R.sup.3 (and R.sup.4 where applicable), and A---B can be as defined herein.